Synbionik

📍 Frankfurt am Main, Germany🗓 Founded 2019👥 3 employees💰 Last funded Jun 2020
Biotechnology Research🌐 synbionik.com
Website LinkedIn
Synbionik designs and creates genetically modified microorganisms and matching bioreactor systems for the production of chemical compounds. This biosynthetic approach leads to drastic cost, purity, and sustainability advantages over traditional production or extraction methods. Synbionik fully embraces advanced laboratory automation technologies with the goal of realizing significant productivity advantages as one of the earliest fully committed adopters in Europe. We currently focus our efforts on the biosynthetic production of cannabinoids. This includes but is not limited to cannabidiol (CBD), cannabigerol (CBG), and tetrahyrocannabinol (THC). Behind the scenes, we are working on other products in our R&D pipeline. Watch this space for updates. Synbionik was founded in early 2019. Its headquarters are in Frankfurt/Main, Germany.
3
Total investors
3
Early stage
0
Mid stage
0
Late stage
2019
Founded

Investors

3 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
Germany
2
Luxembourg
1
Investor activity2019–2020 · investors recorded per year
2019120202
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Synbionik?
Synbionik has 3 investors on record on gritt.io, including 3 early-stage backers.
When did Synbionik last raise funding?
The most recent investment in Synbionik recorded on gritt.io was in June 2020.
When was Synbionik founded?
Synbionik was founded in 2019.
What industry is Synbionik in?
Synbionik operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Synbionik based?
Synbionik is headquartered in Frankfurt am Main, Germany.